Aenova Group

Aenova Group is a leading global contract manufacturing organization (CMO) that provides pharmaceutical and biopharmaceutical development and manufacturing services to the pharmaceutical industry. The company has established itself as a reliable partner for big pharma companies such as Pfizer, Novartis, and Merck & Co., as well as for biotechnology companies like Biogen and Gilead Sciences. With its expertise in formulation development, analytical development, and commercial manufacturing, Aenova Group supports its clients in bringing their medicines to market, from clinical trials to commercial launch, in compliance with FDA and EMA regulations.

Introduction

Aenova Group operates in a highly regulated industry, with a strong focus on quality assurance and compliance with GMP standards, as required by regulatory authorities such as the US FDA and the European Medicines Agency (EMA). The company's services include drug substance manufacturing, drug product manufacturing, and packaging solutions, which are designed to meet the specific needs of its clients, including Roche, Sanofi, and GlaxoSmithKline. Aenova Group's expertise in sterile manufacturing and aseptic filling makes it a preferred partner for companies developing vaccines, such as Pfizer's COVID-19 vaccine, and biologics, such as monoclonal antibodies. The company's commitment to innovation and customer satisfaction has earned it a reputation as a trusted and reliable partner in the pharmaceutical supply chain, working with companies like Johnson & Johnson, AstraZeneca, and Eli Lilly and Company.

History

Aenova Group was founded in 2008 by Andreas Schmid, who had previously worked at Bayer and Boehringer Ingelheim. The company started as a small contract research organization (CRO) providing formulation development and analytical development services to the pharmaceutical industry. Over the years, Aenova Group has expanded its services to include commercial manufacturing and packaging solutions, and has established itself as a leading global CMO, working with clients like Takeda Pharmaceutical Company, Shire plc, and Allergan plc. In 2019, Aenova Group was acquired by BC Partners, a private equity firm that has invested in several other healthcare companies, including Medpace Holdings and Option Care Health. Today, Aenova Group is a global company with operations in Europe, North America, and Asia, and a client base that includes many of the world's leading pharmaceutical and biotechnology companies, such as United Therapeutics, Regeneron Pharmaceuticals, and Incyte Corporation.

Products_and_Services

Aenova Group offers a wide range of products and services to the pharmaceutical industry, including drug substance manufacturing, drug product manufacturing, and packaging solutions. The company's expertise in formulation development and analytical development makes it a preferred partner for companies developing complex generics, such as injectables and topicals. Aenova Group's commercial manufacturing capabilities include sterile manufacturing, aseptic filling, and lyophilization, which are designed to meet the specific needs of its clients, including GSK, Novartis, and Pfizer. The company's packaging solutions include primary packaging, secondary packaging, and labeling, which are designed to ensure the safe and effective delivery of medicines to patients, in compliance with regulations from the FDA, EMA, and WHO. Aenova Group also provides regulatory support and quality assurance services to its clients, including regulatory filings and GMP compliance, working with regulatory bodies like the European Commission and the US Department of Health and Human Services.

Operations

Aenova Group operates a global network of manufacturing facilities, including sites in Germany, Switzerland, France, and the United States. The company's facilities are equipped with state-of-the-art technology and equipment, including clean rooms, lyophilizers, and filling lines, and are designed to meet the specific needs of its clients, including Merck & Co., Sanofi, and Roche. Aenova Group's operations are managed by a team of experienced professionals, including pharmacists, chemists, and engineers, who are dedicated to ensuring the quality and reliability of the company's products and services, in compliance with standards from the International Organization for Standardization (ISO) and the World Health Organization (WHO). The company's global supply chain is managed by a team of experienced logisticians and procurement specialists, who are responsible for sourcing raw materials and excipients from trusted suppliers, including BASF, Evonik Industries, and Covestro.

Management_and_Ownership

Aenova Group is led by a team of experienced executives, including Jan Kyrre, who serves as the company's CEO, and Hermann Kopp, who serves as the company's CFO. The company's management team has a deep understanding of the pharmaceutical industry and a strong track record of delivering growth and innovation. Aenova Group is owned by BC Partners, a private equity firm that has invested in several other healthcare companies, including Medpace Holdings and Option Care Health. The company's ownership structure is designed to support its long-term growth and development, and to enable it to invest in new technologies and capabilities, such as artificial intelligence and machine learning, to stay ahead of the competition, working with companies like IBM Watson Health and Microsoft Health Bot. With its strong management team and ownership structure, Aenova Group is well-positioned to continue its growth and success in the pharmaceutical industry, working with clients like UnitedHealth Group, CVS Health, and Walgreens Boots Alliance. Category:Pharmaceutical companies